Miami, FL – October 4, 2022 – ShiftPixy, Inc. (NASDAQ: PIXY) (“ShiftPixy” or “the Company”), a Florida-based national staffing enterprise which designs, manages, and sells access to a disruptive, revolutionary platform that facilitates employment in the rapidly growing Gig Economy, today announced the successful incubation launch of Quelliv Inc. low level laser centers which provide an effective, non-invasive therapeutic alternative to ease pain, reduce inflammation, enhance skin health, and activate personal well-being. Quelliv laser centers are powered by industry leader Genesis One Lasers to ensure effective sessions with long-lasting results.

“After getting to know the science that powers Quelliv, we were very motivated to help incubate and position Quelliv for a very exciting growth journey,” said ShiftPixy Co-Founder and Chief Executive Officer, Scott Absher. “The incubation process for Quelliv is central to what ShiftPixy Labs does, from taking an initial idea through to funding and mass commercialization. Quelliv is another example of our active engagement process and quest to build large national clients for the unique ShiftPixy platform.”

Quelliv CEO Mike Keyes said, “I have spent a lot of time over the past two years with the ShiftPixy Labs team since the formation of the company, building our business plan, fleshing out our brand, digging through the research and identifying our targeted national locations. The ShiftPixy Labs development team has purpose-built our mobile customer experience to better connect us with our customers and elevate their engagement with the Quelliv brand and experience.”

Quelliv plans to craft a national footprint of 500 centers within twenty-four months of launch, and its first phase of laser centers are already available in Florida at the following locations:

West Palm Beach – 1411 N. Flagler Drive, Ste. 4700, West Palm Beach, FL 33401

Naples – 851 5th Ave. North, Ste. 301, Naples, FL 34102

St. Petersburg – 150 2nd Ave. N, Ste 425, St Petersburg, FL 33701

Upcoming Locations:

Aventura – 18999 Biscayne Blvd, Suite 205, Aventura, FL 33180

Sarasota – 6524 University Parkway, Sarasota, FL 34240

Upcoming Markets:

Nashville; Charlotte; Atlanta; Raleigh Durham; Oklahoma City; Dallas; Austin; Newport Beach

To learn more about Quelliv please visit www.quelliv.com

About Quelliv

Quelliv was designed to introduce a proprietary, high value and high efficacy photobiomodulation technology trained to address a number of biological applications in the wellness market’s highest demand subsectors. Quelliv’s trained laser technology is uniquely applied to anti-aging, weight management, pain management and scalp rejuvenation.  The Company has launched its initial four south Florida locations with two additional locations coming online in Q4 2022. The Company plans to launch a national rollout to major metro markets in Q1 of 2023 with a goal of 500 company owned locations throughout the US longer term.

The company sells its Genesis One photobiomodulation equipment to professional and collegiate sports teams for rapid athlete recovery.

About ShiftPixy

ShiftPixy is a disruptive human capital services enterprise, revolutionizing employment in the Gig Economy by delivering a next-gen platform for workforce management that helps businesses with shift-based employees navigate regulatory mandates, minimize administrative burdens and better connect with a ready-for-hire workforce. With expertise rooted in management’s more than 25 years of workers’ compensation and compliance programs experience, ShiftPixy adds a needed layer for addressing compliance and continued demands for equitable employment practices in the growing Gig Economy.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include, among other things, statements regarding the anticipated use of proceeds from the private placement, the anticipated closing date of the private placement and the anticipated filing and effectiveness date for a registration statement related to the resale of the common shares and common shares underlying warrants from the private placement.  Although such forward-looking statements are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate. If any of the risks or uncertainties, including those set forth below, materialize or if any of the assumptions proves incorrect, the results of the Company, could differ materially from the results expressed or implied by the forward-looking statements we make. The risks and uncertainties include, but are not limited to, risks associated with the nature of the Company’s business model; the Company’s ability to execute its vision and growth strategy; the Company’s ability to attract and retain clients; the Company’s ability to assess and manage risks; changes in the law that affect the Company’s business and its ability to respond to such changes and incorporate them into its business model, as necessary; the Company’s ability to insure against and otherwise effectively manage risks that affect its business; competition; reliance on third-party systems and software; the Company’s ability to protect and maintain its intellectual property; and general developments in the economy and financial markets. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, and its periodic and current reports on Form 10-Q and Form 8-K. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The information in this press release shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD. Further information on these and other factors that could affect the financial results of the Company, is included in the filings we make with the SEC from time to time. These documents are available on the “SEC Filings” subsection of the “Investor Information” section of the Company’s website at https://ir.shiftpixy.com/financial-information/sec-filings, or directly from the SEC’s website at https://www.sec.gov. Consistent with the SEC’s April 2013 guidance on using social media outlets like Facebook and Twitter to make corporate disclosures and announce key information in compliance with Regulation FD, the Company is alerting investors and other members of the general public that the Company will provide updates on operations and progress required to be disclosed under Regulation FD through its social media on Facebook, Twitter, LinkedIn and YouTube. Investors, potential investors, shareholders and individuals interested in the Company are encouraged to keep informed by following us on Facebook, Twitter, LinkedIn and YouTube.

INVESTOR CONTACT:

InvestorRelations@shiftpixy.com

800.475.3655

Source:  ShiftPixy, Inc.

Vancouver, British Columbia, September 22, 2022 – Pangea Natural Foods Inc. (CSE: PNGA) (“Pangea” or the “Company”), a natural food company, is pleased to announce the listing of its Old Fashioned Ghee in all Urban Fare stores located across multiple upscale districts in British Columbia and Alberta.

Urban Fare is a subsidiary of the Pattison Food Group, which is Canada’s largest Western-based provider of food and health products. Headquartered in British Columbia, Canada, Pattison Food Group’s legacy spans a business going back 107 years, and now employs more than 30,000 team members. Currently with 6 locations across Vancouver, Calgary, and Kelowna, Urban Fare is primarily upmarket, with a focus on high-end, gourmet, organic and imported foods.

Effective immediately, Pangea’s Old Fashioned Ghee is now listed in all six Urban Fare locations in British Columbia and Alberta. The Company’s Old Fashioned Ghee is a grass-fed, organic, clarified butter sourced from New Zealand.

Pangea’s CEO, Pratap Sandhu, commented on the Company’s new distribution with Urban Fare, “This is officially our second listing with the Pattison Food Group, as we already sell our products in Save-On-Foods locations. Now having been added to the shelves in all Urban Fare locations, we see this is another vote of confidence testifying the elite quality of our Old Fashioned Ghee product. We look forward to introducing our products to Urban Fare’s customers, who are known for their discerning tastes and their focus on delicious, nutritious and sustainable eating.”

Ghee is a clarified and unsalted form of butter that is caramelized and transformed into pure fat at a high smoking point, with the milk solids removed, meaning even the lactose-intolerant to enjoy the remaining pure ghee.

The Global Ghee Market reached a value of US$45.7 billion in 2021, and is expected to reach US$68.9 billion by 2027, growing at a CAGR of 7.18%.¹

All of the Company’s products are manufactured in the Vancouver lower mainland at an in-house facility approved by both the Canadian Food Inspection Agency and the U.S. Food and Drug Administration. To provide a convenient experience for its customers, the Company offers its products for purchase via e-commerce platforms and traditional retail outlets.

About Pangea Natural Foods Inc.

Pangea Natural Foods Inc. is a food manufacturing company focused on manufacturing and distributing high quality food products across North America.

On Behalf of the Board of Directors

(signed) “Pratap Sandhu”

Pratap Sandhu

CEO, Corporate Secretary and Director

For further information, please visit the Company’s website at www.pangeafood.com or contact:

Pangea Natural Foods Inc.

Pratap Sandhu, Chief Executive Officer

Telephone:         +1 (604) 765-8069

Email:                   pratap@pangeafood.com

1 https://www.imarcgroup.com/ghee-market#:~:text=The%20global%20ghee%20market%20reached,7.18%25%20during%202022%2D2027.

Forward-Looking Information

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the Company’s plans to expand distribution of its products throughout North America and expectations regarding the Company’s growth. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends,” “anticipates,” “it is expected,” or variations of such words and phrases, or statements that certain actions, events or results “may,” “could,” “should,” or “would” occur.

Forward-looking statements are based on certain material assumptions and analyses made by management of the Company and the opinions and estimates of management of the Company as of the date of this news release, including that the Company will be able to widen the distribution of its products in North America and that the Company’s business will grow.  Although the Company considers these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements.  Such risk factors may include, among others, that the Company will not be able to expand its distribution network, and the other risks and uncertainties applicable to the Company and the business of the Company as set forth in the Company’s final long form prospectus dated June 20, 2022 and its other disclosure available under the Company’s profile at www.sedar.com.

There can be no assurance that the transactions contemplated in this news release will complete. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations. We seek safe harbor.

SOURCE:

Pangea Natural Foods Inc.

VANCOUVER, BC , Sept. 7, 2022 /CNW/ – Pangea Natural Foods Inc. (CSE: PNGA) (” Pangea ” or the ” Company “), a natural food company, is pleased to announce the launch of Pangea Munchie Mix, a high-protein snack mix which will be available on Air Canada’s network of flights.

The Company’s Munchie Mix is a superfood rich snack made with dried cranberries, yogurt chips, roasted cashews, almonds and pumpkin seeds. The Company manufactures the Munchie Mix, along with its Plant-Based Patties and Old Fashioned Ghee, in-house at its Vancouver Lower Mainland facility. The Company’s facility has been approved by both the Canadian Food Inspection Agency and the U.S. Food and Drug Administration.

“The introduction of Munchie Mix into Pangea’s product line is yet another opportunity for us to bring high-quality products to the market. All ingredients are free of GMOs and packed with antioxidants, magnesium, manganese, zinc and vitamin E,” says Pangea’s CEO, Pratap Sandhu , “Every step we take to make healthy and nutritious products more accessible for consumers is a step in the right direction and something we constantly strive for at Pangea.”

Pangea’s Munchie Mix will initially be available on Air Canada’s (TSX: AC) fleet of airplanes. Air Canada is Canada’s largest domestic and international airline with a fleet of over 330 aircrafts and serving more than 160 destinations. Together with Air Canada Rouge and Air Canada Express partners, Air Canada provides scheduled passenger service directly to 51 Canadian airports, 46 destinations in the United States and 67 airports in Europe , the Middle East , Asia , and Africa .

Sandhu commented on the Company’s new distribution with Air Canada saying, “We are thrilled to introduce the Munchie Mix to Air Canada’s large network of routes, thus expanding our distribution beyond just an e-commerce and retail footprint.”

To date, the Company offers its other products, the Pangea Plant-Based Patties and Old Fashioned Ghee, via its online website and through over 250 retail outlets across Canada and the United States .

Pangea Natural Foods Inc. is a food manufacturing company focused on manufacturing and distributing high quality food products that are nutritious and free of GMO ingredients, fillers, antibiotics, hormones, and bioengineered ingredients.

On Behalf of the Board of Directors

(signed) “Pratap Sandhu”
Pratap Sandhu
CEO, Corporate Secretary and Director

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the Company’s plans to expand distribution of its products throughout North America and expectations regarding the Company’s growth. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends,” “anticipates,” “it is expected,” or variations of such words and phrases, or statements that certain actions, events or results “may,” “could,” “should,” or “would” occur.

Forward-looking statements are based on certain material assumptions and analyses made by management of the Company and the opinions and estimates of management of the Company as of the date of this news release, including that the Company will be able to widen the distribution of its products in North America and that the Company’s business will grow.  Although the Company considers these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements.  Such risk factors may include, among others, that the Company will not be able to expand its distribution network, and the other risks and uncertainties applicable to the Company and the business of the Company as set forth in the Company’s final long form prospectus dated June 20, 2022 and its other disclosure available under the Company’s profile at www.sedar.com .

There can be no assurance that the transactions contemplated in this news release will complete. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations. We seek safe harbor.

SOURCE Pangea Natural Foods Inc.

Palm Beach, FL –June 4, 2019 – The aging of the worldwide population yearly creates a larger market for the medical device industry. It fuels the expansion of the global and U.S. medical device markets. The World Health Organization, according to an article in Todays Medical Developments, an industry source, said that: “… the geriatric population will reach 1.5 billion by 2050; 16% of the total world population – and as chronic and lifestyle disease increases, demand for medical devices, advanced technology grows.”  SelectUSA (a U.S. Department of Commerce program) has stated that the U.S., the world’s largest medical device market, represents about 40% of the global industry with exports surpassing $41 billion. Todays Medical Developments article added that the global medical technology market is “… is estimated to reach $409.5 billion by 2023 with a compound annual growth rate (CAGR) of 4.5%, according to ResearchandMarkets’ forecast. If you are looking for more opportunity, Evaluate Medtech’s analysts suggest the global medical device market will grow at 5.6% CAGR to reach $595 billion by 2024. Medical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and lifestyle diseases – trends that expand healthcare spending.”    Active Healthcare companies in the markets this week include: Soliton, Inc. (NASDAQ: SOLY), Novartis AG (NYSE: NVS), Amgen Inc. (NASDAQ: AMGN), Medtronic plc (NYSE: MDT), Baxter International Inc. (NYSE: BAX).

The expansion also creates jobs in the market. The article showed that: “Direct and indirect employment accounts for nearly 2 million jobs – medtech directly accounts more than 500,000 – and while 80% of medical device companies in the United States consist of fewer than 50 employees, the medtech industry employs people in all 50 states.”  It concluded that medical technology devices: “… must be produced better, safer, faster, and more economically to have the best chance for market acceptance, so early-stage collaboration requires a design for manufacturability (DFM) approach. Enabling proactive designing of products to optimize manufacturing: machining, fabrication, assembly, test, procurement, shipping, delivery, service, and repair, DFM addresses aspects that will deliver the best cost, quality, reliability, regulatory compliance, safety, time-to-market, and customer satisfaction.”

Soliton, Inc. (NASDAQ: SOLY) BREAKING NEWS:  Soliton, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced results of preclinical studies of the use of a new version of its acoustic pulse technology which reveal its RAP device appears to be capable of selective disruption of the fibrotic septa that contribute to the appearance of cellulite.  The new discovery, referred to as “acoustic subcision,” helps explain the recent proof-of-concept trial results showing an improvement in the appearance of cellulite following use of the Company’s RAP device.  Together with the device’s demonstrated ability to stimulate new collagen production in animal models, this represents what the Company believes is a potentially important new way to treat cellulite and improve the appearance of the skin.  The RAP device for the treatment of cellulite is investigational and not available for sale in the United States.

“While the proof-of-concept clinical trial results we have recently announced regarding the improvement in the appearance of cellulite have been very encouraging,” commented Dr. Chris Capelli, President and CEO of Soliton, “Understanding the basic science and biology behind these results is very important.  We believe the discovery we are outlining here helps explain the promising results we saw from this trial, as well as setting the foundation for a platform technology that may have potential in a number of aesthetic indications.”

The term ‘subcision’ normally refers to a surgical procedure used to sever the fibrotic septa using a special hypodermic needle, punctured through the skin, in order to allow the dimpled skin associated with cellulite to return to a flatter, smoother state. This procedure is typically painful enough that anesthesia is required. Futhermore, this surgical procedure can result in extensive bruising, bleeding or post-treatment discomfort and downtime.  Our use of the term ‘acoustic subcision’ describes the apparent ability of our RAP technology to do this without ever breaking the skin.  What’s more, the procedure should require no anesthesia and importantly, as seen in our clinical trial, there should be no bruising, bleeding or post-treatment discomfort or downtime.  See Illustrations and Read this entire release along with more news for SOLY at:   https://financialnewsmedia.com/news-soly/   

Other recent developments in the healthcare, biotech industries:

Novartis AG (NYSE: NVS) recently announced new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from the GEOMETRY mono-1 Phase II clinical trial demonstrating that investigational MET inhibitor capmatinib (INC280) shows promise as a potential treatment option for patients with locally advanced or metastatic NSCLC that harbor MET exon-14 skipping mutation. There are currently no approved targeted therapies to treat this particularly aggressive form of NSCLC. Results of the Phase II study will be presented at an oral session today at ASCO, June 3, 2019, at 8:00 a.m. CDT (Abstract #9004).

“New lung cancer treatment options are critical, as this deadly disease affects more than 2 million new patients around the world each year,” said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis. “The GEOMETRY mono-1results are encouraging, and we look forward to discussing these results with health authorities with the hope of bringing this targeted treatment option to people with this aggressive type of lung cancer.”

Amgen Inc. (NASDAQ: AMGN) recently announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRAS^G12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels. AMG 510 showed anti-tumor activity when administered as a monotherapy in patients with locally-advanced or metastatic KRAS^G12Cmutant solid tumors. These data are being presented during an oral session at the 55^thAnnual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

“KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago, but it remained undruggable due to a lack of traditional small molecule binding pockets on the protein. AMG 510 seeks to crack the KRAS code by exploiting a previously hidden groove on the protein surface,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “By irreversibly binding to cysteine 12 on the mutated KRAS protein, AMG 510 is designed to lock it into an inactive state. With high selectivity for KRAS^G12C, we believe investigational AMG 510 has high potential as both a monotherapy and in combination with other targeted and immune therapies.”

Medtronic plc (NYSE: MDT) recently announced U.S. Food and Drug Administration (FDA) clearance and commercial launch for the SelectSite(TM) C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing (HBP).

The SelectSite C304-HIS deflectable catheter system features a deflectable, out-of-plane curve to reach the bundle of His and is designed to enable enhanced range maneuverability, fixation and implant success for a wider range of patient anatomies. Its adjustable form helps accommodate and secure the pacing lead in more challenging anatomies, including patients with a large right atrium.

Baxter International Inc. (NYSE: BAX) a global leader in acute care therapies, recently announced that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis. The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy this week, add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions.

The use of EBP to remove cytokines and endotoxin from the blood represents a promising approach to treat patients with conditions where excessive levels of those inflammatory mediators are often seen including sepsis, a serious medical condition that affects up to 40 percent of critically ill patients in the ICU.^1-7 While EBP continues to be studied for its potential to help address sepsis and other conditions, clinical research is particularly challenging in this setting. In fact, many clinical trials that explored the effect of EBP have failed to demonstrate consistent results due to the complexity of patient cases, among other factors. To help address these limitations, Baxter intends to support the creation of the OxirisNet registry with several Italian hospitals to track key treatment data for patients who receive a treatment with the Oxiris filter. The new registry will use a web-based platform specifically designed for research purposes and will be fed by clinical data that are prospectively collected.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Soliton, Inc. by the company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

SOURCE Financialnewsmedia.com

Palm Beach, FL –May 29, 2019 –  Cellulite affects 85% to 90% of all women worldwide and was first described nearly 100 years ago… and has been the bane of women (and men) ever since. But to find a ‘cure’ or effective ‘solution’ the cause must be understood. First of all, cellulite is a cosmetic problem, not a disease process. It isn’t harmful, but it is a serious cosmetic concern for those people who want to feel better about their appearance. According to dermatology sites, causes may be genetic, hormonal, or vascular in nature and may be related to the septa configuration in the subdermal tissue. Fibrosis at the dermal-subcutaneous junction as well as decreased vascular and lymphatic circulation also may be causative factors.   Consumers are also now, more inclined, to try modern technical solutions as technology has increased the available alternatives. Reports suggest that there is growing demand from consumers, especially those with disposable income, to look for non-herbal, non-invasive solutions to combat cellulite. “Non-invasive is a highly lucrative market that leads in terms of market value and growth rate during the forecast period. In non-invasive procedure ultrasound, radiofrequency technology, infrared light etc., are used to destroy the fat… “    Active Healthcare companies in the markets this week include: Soliton, Inc. (NASDAQ: SOLY), Shockwave Medical, Inc. (NASDAQ: SWAV), Pfizer Inc. (NYSE: PFE), Sesen Bio, Inc. (NASDAQ: SESN), Boston Scientific Corporation (NYSE: BSX).

According to an industry publication: “… the market for non-invasive treatment is expected to reach a value of over US$ 1,900 Mn by the end of 2028, growing at a robust CAGR of 8.0% during the forecast period.  This is followed by minimally invasive treatment which secures the second position in the market… The market for minimally invasive treatment is expected to witness a growth rate of 7.8% during the projection period…. Significant rise in the world’s middle-class population over the next few years will result in increase in the purchasing power and discretionary spending, which are the key factors responsible for the stability and growth of (the) market worldwide.”

Soliton, Inc. (NASDAQ: SOLY) BREAKING NEWS:  Soliton, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced its decision to move forward with a pivotal trial in cellulite after positive data from its proof of concept clinical trial for the reduction of cellulite (the “POC Trial”) confirmed.

The Pivotal cellulite study is being designed to take place at multiple clinical sites across the country with between 45 and 60 patients to be treated in the study.  We hope to begin the study within the next three months.

Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the U.S.  Now, results from this Trial suggest the potential for a totally new approach to treating cellulite. In a single 20-minute, non-invasive treatment, the Rapid Acoustic Pulse (RAP) device was applied to the surface of the patients’ skin.  The treatments required no anesthesia, caused no bruising, swelling or bleeding, and were evaluated as relatively painless by the trial participants, none of whom experienced any post-treatment discomfort or downtime.  The data was originally presented at the SCALE (Symposium for Cosmetic Advances and Laser Education) conference in Nashville, Tennessee, by Dr. Elizabeth Tanzi on May 11, 2019.

The POC Trial involved a study of five patients with moderate to severe cellulite, each treated on their thighs, with a new higher-powered version of Soliton’s RAP device. While the Company’s RAP device intended to assist in tattoo removal was recently cleared by the FDA, this higher-powered version will require a new application for clearance for the cellulite indication.  In the POC Trial, approximately 97% of treatments were rated 0 on a 0 to 10-point pain scale (with 0 being no pain). At the end of the 12-week POC Trial, in a blinded review by doctors of before and after photos, 100 percent correctly identified which photo was the “after.”  The three blinded reviewers, who are trained in the use of the cellulite severity scoring system, scored the before and after photos using the 5-point system.  100% of the patients showed clinical improvement.  The range of improvement in cellulite severity score was 20% to 47% and the average improvement for all patients was nearly a 30% improvement (1.24 reduction on the 0 to 5-point cellulite severity scale).  As a point of reference, the only FDA approved method for long-term reduction of cellulite is an invasive treatment called Cellfina that produced an average improvement on the same scale of about 2 points.  However, this is a procedure requiring topical anesthesia, penetration of the skin and involves potential bleeding, bruising and significant post-treatment discomfort and downtime.  We believe Soliton RAP involves none of these potential negatives.

“The market for non-invasive cellulite treatments is about $1 billion in the U.S., so it is clear that many women who are affected by the condition are interested in finding ways to reduce or eliminate it,” said Walter Klemp, co-founder and Executive Chairman of Soliton. “The very encouraging results of the POC Trial are driving our decision to launch the pivotal trial as quickly as possible and suggest we may be able to significantly improve the appearance of cellulite with a single completely non-invasive procedure. The procedure requires no recovery time and avoids the risks that go with even minimally invasive surgery.”    Read this and more news for SOLY at:   https://financialnewsmedia.com/news-soly/  

Other recent developments in the healthcare, biotech industries:

Boston Scientific Corporation (NYSE: BSX) has recently initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (OAC) – including direct oral anticoagulants (DOAC) and warfarin – for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) who undergo a cardiac ablation procedure.

Approximately 33 million patients worldwide have AF, a common heart rhythm disorder. In recent years, the number of U.S. patients who have undergone an in-hospital cardiac ablation procedure to prevent abnormal electrical signals from moving through the heart has grown tenfold. More than 50% of those patients become asymptomatic, making them less likely to adhere to current guidelines recommending the continuation of OAC post-procedure to reduce the risk of stroke. Stroke is five times more likely to occur in patients with AF than in someone with a normal heart rhythm.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced this month that the Company has appointed Keith D. Dawkins, M.D. as Chief Medical Officer.

“Given the challenges associated with treating calcium throughout the cardiovascular system, joining Shockwave and contributing to the development of what will likely become the new standard of care for calcium modification was an attractive opportunity,” said Dr. Dawkins. “The Company has made significant progress in the last year in both technology development and the successful application of IVL to a variety of clinical settings; I believe that the future potential of IVL has yet to be fully realized.”

Sesen Bio, Inc. (NASDAQ: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, recently announced that the Company has completed its Type C CMC meeting and has reached agreement with the U.S. Food and Drug Administration (FDA) on the Analytical Comparability Plan, and that, subject to final comparability data to be provided in the BLA submission, no additional clinical trials to establish comparability are deemed necessary at this time.

In its Phase 2 and 3 clinical trials, Sesen Bio manufactured Vicinium in its facility in Winnipeg, Manitoba. Based on the Company’s assessment of the global demand potential for Vicinium, Sesen Bio sought a commercial manufacturer with outstanding manufacturing quality, a proven track record with regulatory agencies, and the capacity to meet global demand forecasts.

Pfizer Inc. (NYSE: PFE) recently announced that a Phase 3 study to assess the use of LYRICA^® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint. Treatment with LYRICA did not result in a statistically significant reduction in seizure frequency versus placebo. Lyrica is not indicated in any population for the treatment of PGTC seizures. The study was a post-marketing commitment to the U.S. Food and Drug Administration (FDA).

“Pfizer is committed to the study of patient populations with unmet treatment needs, including pediatric and adult patients experiencing generalized tonic-clonic seizures,” said Juan Ovalle, M.D., Global Chief Medical Officer, R&D and Medical, Upjohn, a division of Pfizer. “These data contribute to our growing understanding of pediatric epilepsy and reflect our responsibility to advance scientific knowledge through post-marketing research.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Soliton, Inc. by the company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

SOURCE Financialnewsmedia.com

Dr. Elizabeth Tanzi to Present Soliton’s Cellulite Data at Music City SCALE 2019 Conference in Nashville, TN

Houston, TX – April 15, 2019 –Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that Dr. Elizabeth Tanzi of Capital Laser and Skin Care will present preliminary data from its completed cellulite clinical trial at the SCALE (Symposium for Cosmetic Advances and Laser Education) conference in Nashville, Tennessee to be held May 9-11, 2019.

The proof of concept study, conducted by Dr. Michael Kaminer at SkinCare Physicians in Boston, MA, in collaboration with Dr. Tanzi, was designed to evaluate the safety and efficacy of Soliton’s acoustic pulse device for the reduction of cellulite.  The data presented will reflect results from a single acoustic pulse treatment, operating at a higher power level than the Company’s RAP device intended for tattoo removal, at the 12-week timepoint. Dr. Tanzi will also review preclinical data that appears to support what the Company believes may be a new method for treating cellulite.

————————

Join our more than 200K fans here to follow the Company: https://soly-investors.com

————————

“There has been a lot of anticipation surrounding the potential for our technology as a stand-alone treatment for cellulite,” commented Dr. Chris Capelli, President and CEO of Soliton, “especially considering the preclinical data suggesting that our unique acoustic pulses may be capable of achieving results only thought possible with invasive therapies.  Considering that our technology is non-invasive and has been well tolerated by our trial participants, our goal has been to deliver clinically significant results without patient discomfort or downtime.  We believe the upcoming presentation by Dr. Tanzi will be an important indicator of our progress and potential.”

Drs. Kaminer and Tanzi are members of Soliton’s Advisory Board.

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications.    Both products are investigational and are not available for sale in the United States.

For more information about the Company, please visit:  http://www.soliton.com

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton’s acoustic shockwave device to reduce cellulite in the proof of concept clinical trial. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading “Item 1A. Risk Factors” in the Form 10-K for year ended December 31, 2018 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT:

Joe Dorame, Joe Diaz & Robert Blum

Lytham Partners, LLC

602-889-9700

soly@lythampartners.com

Source:  Soliton, Inc.

Palm Beach, FL – March 4, 2019 – Medical technology is an area where the U.S. companies are at the forefront. In fact, according to recent industry publication the: “U.S. remains the largest medical device market in the world, with a market size of around $156 billion as well as representing about 40 percent of the global medical device market last year alone… Compared to several other industries including automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation, reflecting the competitive nature of the industry and constant innovation and improvement of existing technologies.   The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development. Collaborations have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector’s ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future.”    Active Healthcare companies in the markets this week include: Soliton, Inc. (NASDAQ: SOLY), Bio-Path Holdings, Inc. (NASDAQ: BPTH), TG Therapeutics, Inc. (NASDAQ: TGTX), Puma Biotechnology, Inc. (NASDAQ: PBYI), Amarin Corporation plc (NASDAQ: AMRN).

FORBES calls the medical device market a: “A disruptive market of $410 billion until 2023… Software plays a big part in this shift as a differentiator in medical devices as well as the manufacturing  of portable devices used by the end user.”

Soliton, Inc. (NASDAQ: SOLY) BREAKING NEWS:  Soliton, a medical device company with a novel and proprietary platform technology licensed from The University of Texas M.D. on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has received notice from the U.S. Food and Drug Administration (“FDA”) that the Company has qualified for the “Small Business” designation under the Medical Device User Fee Amendments (“MDUFA”). As a Small Business under the MDUFA, Soliton qualifies for a reduce or waived fee for medical device submissions made during the fiscal year 2019.  Join our more than 208K fans here to follow the Company: https://soly-investors.com

Dr. Christopher Capelli, president and CEO of Soliton, said, “We are pleased to have qualified for Small Business status allowing us to receive reduced or waived fees for our FDA submissions. We appreciate the opportunity to submit device applications for review and approval at more favorable rates. In certain submissions, the savings could be dramatic. This helps us to operate more efficiently. Our plan is to is to submit our Rapid Acoustic Pulse (“RAP”) device for tattoo removal for premarket clearance with the FDA under our new status in the near future.”

The MDUFA rates cover a number of submissions that are routinely made to the FDA for review and approval. The rate table assigns fees for the fiscal year – which ends on September 30, 2019 – for the application type submitted for review along with the Standard Fee and the Small Business fee for companies that qualify for the designation.      Read this and more news for SOLY at:  https://financialnewsmedia.com/news-soly/

Other recent developments in the healthcare, biotech industries:

Bio-Path Holdings, Inc. (NASDAQ: BPTH) On February 28, the company,  a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting, taking place from March 29 – April 3, 2019 in Atlanta, GA.

Details for the poster presentation are as follows:

Date: Wednesday, April 3, 2019
Presentation Time: 8:00 am – 12:00 pm Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B
Session: Gene- and Vector-Based Therapy, Poster Section 12

TG Therapeutics, Inc. (NASDAQ: TGTX) recently announced approximately $85 million in equity and debt financing.  The Company priced a public offering of its common stock for gross proceeds of approximately $25.2 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase $3.8 million of additional shares of common stock. All of the shares in the offering are being sold by the Company. The Company anticipates using the net proceeds from the offering to fund the ongoing development of ublituximab and umbralisib, for research and development activities and for general corporate purposes. The offering is expected to close on March 5, 2019 subject to customary closing conditions.

Puma Biotechnology, Inc. (NASDAQ: PBYI) recently announced fourth-quarter results and 2019 guidance Thursday that were ahead of expectations, boosting confidence in Nerlynx achieving a global product revenue estimate of $683 million in 2023, according to Cantor Fitzgerald. Cantor Fitzgerald’s Alethia Young maintained an Overweight rating on Puma Biotechnology and raised the price target to $57.

The LA-based pharmaceutical company reported strong fourth-quarter results, with U.S. Nerlynx sales of $61 million handsomely beating the consensus expectation of $53 million. Puma Biotechnology guided to 2019 U.S. Nerlynx sales of $255-$280 million, exceeding the consensus estimate of $238 million.

Amarin Corporation plc (NASDAQ: AMRN) recently announced  that John F. Thero, Amarin’s president and chief executive officer, presented a general company update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m. Eastern Time in New York City.

A live audio webcast of the presentation will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa^® (icosapent ethyl) is Amarin’s first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates.  Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated nineteen hundred dollars for news coverage of the current press releases issued by Soliton, Inc. by the company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

SOURCE Financialnewsmedia.com

VANCOUVER, B.C., February 6, 2019 – NetCents Technology Inc. (“NetCents” or the “Company”) (CSE: NC/ Frankfurt: 26N), is pleased to announce that the integration into the ExaDigm, Inc. (ExaDigm) N5 smart terminal has been completed.

“The NetCents integration into our N5 terminal represents another way we provide our customers and their customers the latest and greatest in payment options,” Patricia Love, Vice President of ExaDigm, Inc., says. “Making it easier to spend cryptocurrency for day-to-day purchases is a big leap for all of us.”

ExaDigm is a leader in Point-of-Sale (POS) terminal solutions. ExaDigm has developed a range of point-of-sale terminals, such as mobile payment terminals, countertop payment terminals, mobile point-of-sale solutions, smart PIN pads, and compact mobile payment terminals. ExaDigm services retail, foodservice, transportation, events and venues, as well as home services industries worldwide.

The N5 POS terminal allows for multiple payment types including NFC, EMV, pin-based transactions, and signature capture. Now, with the integration of the NetCents cryptocurrency merchant gateway, cryptocurrency. The terminal is certified for TYSYS and can process as a stand-alone solution or semi-integrated with a POS solution.

“The successful integration of the NetCents platform into ExaDigm N5 POS terminal is milestone for both NetCents and the acceptance of cryptocurrency as a daily transactional currency,” stated Clayton Moore, CEO of NetCents. “Through this integration we have now made it easier for merchants to accept and cryptocurrency holders to spend their cryptocurrency in brick and mortar locations.”

ExaDigm’s hardware is also integrated within the SoftPoint software through their All-in-One payment integrated terminal. With the addition of the NetCents cryptocurrency merchant gateway into both ExaDigm and SoftPoint, the strategic relationships provide merchants a seamless method to accept cryptocurrency payments in the card present environment.

About ExaDigm, Inc.

ExaDigm offers a one-stop payment solution for hardware and wireless needs. ExaDigm provides affordable and customizable payments solutions and wireless communication services that enable businesses worldwide to perform payment transactions confidently, securely, and efficiently. This effort includes purpose-built terminals that meet EMV requirements, provide integrated solutions, and offer dedicated personalized support. As a leading provider of wireless data solutions, ExaDigm Wireless meets the needs of businesses requiring end-to-end device-managed connectivity, offering stand-alone retail and wholesale solutions, failover solutions, as well as a wireless value bundle. For more information, visit http://www.exadigm.com.

About NetCents

NetCents is a next-generation online payment processing platform, offering consumers and merchants online services for managing electronic payments. The Company is focused on capturing the migration from cash to digital currency by utilizing innovative Blockchain Technology to provide payment solutions that are simple to use, secure and worry free. NetCents works with its financial partners, mobile operators, exchanges, etc., to streamline the user experience of transacting online. NetCents Technology is integrated into the Automated Clearing House (“ACH”) and is registered as a Money Services Business (MSB) with FINTRAC, which ensures our consumer’s security and privacy. NetCents is available for deposits from 194 Countries around the World, providing you with the freedom to choose to Pay. Your Way. ™

For more information, please visit the corporate website at www.net-cents.com or contact Gordon Jessop, President / COO at: gord.jessop@net-cents.com.

On Behalf of the Board of Directors

NetCents Technology Inc.

“Clayton Moore”

Clayton Moore, CEO, Founder and Director

NetCents Technology Inc.

Suite 880, 505 Burrard St (Bentall 1),

Vancouver, BC, V7X 1M4

Cautionary Note Regarding Forward Looking Information

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The CSE has not reviewed, approved or disapproved the content of this press release

Source:  NetCents Technology Inc.

Santa Monica, CA, Dec. 19, 2018 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mrs. MaryAnn Edzards as Senior Director – Account Manager.Mrs. Edzards brings to the Company over 10 years of experience in electrophysiology (EP), including six years at Biosense Webster, a Johnson & Johnson company. Most recently, she served as New Technology Education Manager, a role, in which she was responsible for all internal and external marketing and training programs for two global product launches. Mrs. Edzards facilitated training of over 300 field and in-house employees and delivered impactful training modules for complex technologies through virtual and live classroom environments. She brings to BioSig extensive experience in converting Voice of Customer feedback into commercially valuable solutions. Mrs. Edzards is a holder of numerous Johnson & Johnson awards, including 2016 Standards of Leadership Award and 2017 Gold Encore Award from Commercial Marketing.

“A high-performing and motivated professional like MaryAnn is an invaluable addition to our commercial team. Her expertise in delivering highly impactful education and training of both in-house professionals and physicians will tremendously benefit our efforts during the vital First-in-Human patient data collection phase and subsequent market launch in 2019,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.

The Company announced that it received the 510(k) clearance for its PURE EP™ System on August 14, 2018. BioSig announced on November 28, 2018 that it begins installations of the first systems at Texas Cardiac Arrhythmia Institute in Austin, Texas, followed by another announcement on December 6, 2018 about enrolling Mayo Clinic as the second center for the First-in-Human studies. BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017 and announced a new research agreement focusing on development of additional advanced features and potential new applications of PURE EP™ System on November 13, 2018.

“I’m excited to join the BioSig team as the Company commences first installations of PURE EP™ System in some of the leading medical centers of excellence. There is a pressing need for better technological solutions in the space of arrhythmia treatments, and I look forward to contributing my knowledge and expertise to help the Company bring its novel platform onto the market,” commented Mrs. Edzards.

About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12600 Hill Country Blvd R-275
Austin, TX 78738
ndrapeau@biosigtech.com
512-329-2643

Source: BioSig Technologies, Inc.

Palm Beach, FL – (December 13, 2018) – Vanadium has made a huge comeback in 2018. Vanadium’s price rise in 2018 has been nothing short of spectacular rising dramatically from USD $20/lb to above USD $33/lb in October 2018.  Prices in China have more than tripled over the course of 2018 as a result of Chinese construction laws requiring vanadium to be used in steel rebar.  Vanadium and Energy storage is also a very important disruptive trend resulting in a growing demand for vanadium redox flow batteries which involves storing energy that can later be harnessed for electricity to power our homes, our cars – our future. The International Renewable Energy Agency (IRENA) states Batteries for energy storage could reach 250GW by 2030 as demand for Energy Efficient Batteries is generating new levels of growth.  Active mining companies in the markets this week include Delrey Metals Corp.  (CSE:DLRY) (FSE:1OZ), Albemarle Corporation (NYSE:ALB), Largo Resources Ltd. (TSX:LGO) (OTC:LGORF), Katanga Mining Limited (TSX:KAT) (OTC:KATFF), First Vanadium Corp. (TSX-V:FVAN) (OTC:FVANF).

Delrey Metals Corp.  (CNX:DLRY) (FSE:1OZ)  BREAKING NEWS:  Delrey Metals Corp is pleased to announce it has entered into and closed a share purchase agreement dated December 12, 2018 (the “Share Purchase Agreement”) with WEM Western Energy Metals Ltd., a private arm’s length corporation (“WEM”), to acquire all the issued and outstanding share capital of WEM.  Pursuant to the terms of the Share Purchase Agreement, the Company issued 4,250,000 common shares of the Company (each, a “Share”). All securities issued pursuant to the Share Purchase Agreement will be subject to a four month statutory hold period.

WEM owns a 100 percent undivided, unencumbered legal and beneficial interest in both the Peneece and the Blackie Vanadium properties (the “Properties”), located in British Columbia. The Properties cover a total area of 2,714 hectares and host vanadium mineralization within large bodies of titaniferous magnetite. Both properties are strategically located on tidewater, near to the small coastal cities of Port Hardy (Peneece – 68km) and Prince Rupert (Blackie – 96km).

About the Peneece and Blackie Vanadium Projects:

The Properties are comprised of large-scale ultramafic complexes which are intruded by gabbroic bodies hosting iron-titanium-vanadium (Fe-Ti-V) mineralization within massive titaniferous magnetite. Two of the gabbro bodies mapped on surface display lateral extents of 4.8km x 0.8km (Peneece) and 1.2km x 0.4km (Blackie).

Highlights:

• Historic samples collected from the gabbro on the Blackie assay up to 2.14% V₂0₅.¹
• The Blackie property is located in a historic mining district. The adjacent past-producing Yellow Giant Mine, located less than 10km from the property and operated by Banks Island Gold as recently as 2015 initially boasted a 414% IRR, showing the economic potential that exists on Banks Island².
• McDougall (1984), commented that, “an unusually strong and extensive magnetic anomaly exists over the [Peneece Property]. It was, and still remains the largest flux gate magnetic anomaly noted by the writer during many years of work on the West Coast. The size and overall magnetic intensity of the anomaly were only exceeded at the multi-billion ton “Klukwan pyroxenite-amphibolite” deposit in S.E. Alaska.”
• Magnetic concentrate from limited float samples collected distal to the magnetic anomaly on the Peneece Property assayed up to 0.59% V₂0₅.¹
• Both properties are easily accessible by boat or helicopter and workable year round. Historic barge-logging was completed within and near to the project areas, which has created a network of logging roads and allows for low cost exploration and development.

An initial work program including a high-resolution airborne magnetic survey is planned in the near term on both Properties.     Read this and more news for Delrey Metals Corp at https://financialnewsmedia.com/news-dlry

Other recent developments in the mining industry include:

Largo Resources Ltd. (TSX:LGO.TO) (OTCQX:LGORF) recently announced  record cash provided before non-cash working capital items of $127.5 million and basic earnings per share of $0.14 on record revenues of $149.5 million during the third quarter 2018. Production at the Maracás Menchen Mine for the quarter was 2,563 tonnes of V2O5, representing a new quarterly production record and the Company’s strongest quarter of production to date. Mark Smith, Chief Executive Officer for Largo, stated “Largo delivered robust financial performance as a result of record operational output from the Maracás Menchen Mine in the third quarter. The Company also reported the highest ever revenues and operating cash flows to date of $149.5 million and $113.4 million , respectively, and continues to strengthen its balance sheet every quarter. Production at the Maracás Menchen Mine continued to be strong delivering its best quarter of the year with record production of 2,563 tonnes of V2O5. We continue to advance the expansion project at the Maracás Menchen Mine and the Company remains on track to achieve its increased production guidance for 2018.”

Albemarle Corporation (NYSE:ALB) recently announced it  has signed an Exclusivity Agreement (Agreement) with Mineral Resources Limited (MIN.AX) in relation to the potential creation of a 50/50 joint venture (JV) to own and operate the Wodgina hard rock lithium mine and ultimately develop an integrated lithium hydroxide operation at the resource site. Wodgina, located in the Pilbara region of Western Australia, is a world-class hard rock lithium deposit, with an estimated mine life of over 30 years. The proposed JV, which remains subject to negotiation of definitive documents, would combine Albemarle’s world-class lithium production and marketing expertise with Mineral Resources Limited’s (MRL) leading regional presence and mining capabilities. Under the terms of the Agreement, Albemarle would manage the marketing and sales of lithium hydroxide produced by the JV via Albemarle’slong term agreement strategy.

First Vanadium Corp. (TSX-V:FVAN.V) (OTCQX:FVANF) recently announced that it has negotiated the purchase of a 1.5% NSR attached to its Carlin Vanadium property in consideration for which it will issue 1,300,000 common shares of the Company to the owner of the NSR. The shares, when issued, will be subject to a hold period expiring four months plus a day after the date of their issuances in compliance with Canadian securities laws. The completion of this purchase is subject to TSX Venture Exchange acceptance. Paul Cowley, President of the Company, stated: “This is a unique opportunity for us at this time to extinguish a 1.5% NSR on the Carlin Vanadium Property and associated advanced royalty payments, all at a deep discount of roughly 67% to the original US$3 million buy-back price established for this NSR. This preserves and focuses our treasury on advancing the project. Upon completion of this transaction, only a 2% NSR will remain attached to the property, with the Company retaining the rights to purchase the remaining NSR for US$4 million.”

Katanga Mining Limited (TSX:KAT.TO) (OTCPK:KATFF) recently announced that it has successfully completed the hot commissioning of Phase 2 of its whole ore leach (“WOL”) processing facility at its 75% owned subsidiary Kamoto Copper Company’s (“KCC”) copper and cobalt mine in Lualaba Province, DRC. The commissioning of the pre-leach circuits is continuing as scheduled and is expected to be completed by the end of 2018. A progressive ramp-up of the facility is expected to follow with the objective of achieving full capacity of the WOL plant by the end of Q1 2019.  Johnny Blizzard , Chief Executive Officer of Katanga, commented: “We are very pleased to have entered into the final phase of the commissioning of the WOL processing plant project after three years of hard work. Following the commissioning of Phase 1 last year, and the commissioning of Phase 2, we are already seeing the benefits of improved recoveries, more predictable plant performance and looking forward to increasing production.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks..  For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Delrey Metals Corp. by the company.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

SOURCE Financialnewsmedia.com